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Abstract
Background: Oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are amides of fatty acids and ethanolamine
named N-acylethanolamines or acylethanolamides. The hydrolysis of OEA and PEA is catalyzed by the fatty acid amide
hydrolase (FAAH). A number of FAAH inhibitors that increase the levels of OEA and PEA in the brain have been developed,
including URB597. In the present report, we examined whether URB597, OEA or PEA injected into wake-related brain areas,
such as lateral hypothalamus (LH) or dorsal raphe nuclei (DRN) would promote wakefulness (W) in rats.
Methodology and Principal Findings: Male Wistar rats (250–300 g) were implanted for sleep studies with electrodes to
record the electroencephalogram and electromyogram as well as a cannulae aimed either into LH or into DRN. Sleep stages
were scored to determine W, slow wave sleep (SWS) and rapid eye movement sleep (REMS). Power spectra bands underly
neurophysiological mechanisms of the sleep-wake cycle and provide information about quality rather than quantity of
sleep, thus fast Fourier transformation analysis was collected after the pharmacological trials for alpha (for W; a=8–12 Hz),
delta (for SWS; d=0.5–4.0 Hz) and theta (for REMS; h=6.0–12.0 Hz). Finally, microdialysis samples were collected from a
cannula placed into the nucleus accumbens (AcbC) and the levels of dopamine (DA) were determined by HPLC means after
the injection of URB597, OEA or PEA. We found that microinjection of compounds (10, 20, 30 mg/1 mL; each) into LH or DRN
during the lights-on period increased W and decreased SWS as well as REMS and enhanced DA extracellular levels.
Conclusions: URB597, OEA or PEA promoted waking and enhanced DA if injected into LH or DRN. The wake-promoting
effects of these compounds could be linked with the enhancement in levels of DA and indirectly mediated by anandamide.
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Introduction
Amides of long-chain fatty acids with ethanolamine are a family
of lipids mediators produced through the action of two enzymes:
N-acyl-transferase and phospholipase D [1,2]. Fatty acids with
ethanolamine (FAE) can be hydrolyzed by the fatty acid amide
hydrolase (FAAH; [3]). To this date, a number of FAAH inhibitors
have been described [2,3], including URB597. Several reports
have indicated that URB597 inhibits FAAH activity in vitro rat
brain membranes with an IC50 value of 5 nM. Likewise this drug
has a remarkable selectivity for FAAH with no activity on other
cannabinoid-related elements [4–8].
Multiple physiological roles for FAE have been proposed. For
instance, oleoylethanolamide (OEA) is related with mechanisms of
satiety [9,10], activates a PPAR-a receptors [11] and it has been
related with fat ingestion [12] whereas palmitoylethanolamide
(PEA) acts as an antinociceptive molecule [13,14] and displays
anti-inflammatory properties [15].
Previously, we have shown that intracerebroventricular (icv)
injections of URB597, OEA or PEA in rats increase alertness,
enhance dopamine (DA) and induce c-Fos expression in wake-
related brain areas, such as lateral hypothalamus (LH) or dorsal
raphe nuclei (DRN) [16]. This result prompted us to question
whether these compounds might enhance waking if injected
directly into these two brain areas linked with the sleep-wake cycle
modulation [17–19].
A second aim of the present study was to determine if
microinjections of URB597, OEA or PEA would increase DA
levels collected from nucleus accumbens (AcbC) if administered
into LH or DRN. The AcbC was selected as a target for collection
of DA due its importance in the modulation of the sleep-wake
cycle [20–22]. Thus, it was reasonable to hypothesize whether
URB597, OEA or PEA would increase waking if injected into LH
or DRN and these compounds may enhance the contents of DA
collected from AcbC.
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Figure 1 display schematic drawings from the rat brain atlas [23]
showing the localization of the cannulae placed at DRN (Panel A),
LH (Panel B) or the microdialysis probe position into AcbC (Panel
C). Rats whose cannulae or microdialysis probe placements fell
outside of the target areas were excluded from further analysis.
Effects on sleep after the microinjection of URB597, OEA
or PEA into LH
In the whole report, no statistical differences were found among
sham and VEH groups. Next, in experiment 1, URB597 (10, 20, or
30 mg/1 mL) injected into LH increased W (p,0.001) and decreased
SWS (p,0.001) and REMS (p,0.001; Figure 2A). A dose-dependent
effect was found in W and SWS after microinjection of URB597. In
the OEA intrahypothalamic trial (10, 20, or 30 mg/1 mL; Figure 2B),
waking was enhanced (p,0.001) whereasSWS(p,0.001) and REMS
(p,0.001) were diminished. Furthermore, a dose-dependent response
in W and SWSusingOEAwas observed.Similarly,PEAinjected into
LH enhanced waking (p,0.01) but decreased SWS (p,0.01) and
REM (p,0.01; Figure 2C).
Effects on sleep after the microinjection of URB597, OEA
or PEA into DRN
In the next experiment, injection of URB597 (10, 20, or 30 mg/
1 mL; Figure 3A) into DRN promoted waking (p,0.001) and
Figure 1. Schematic drawings from rat brain atlas [23] showing a vertical black bar that represents the localization of the cannulae
placed at DRN (Panel A), LH (Panel B) or the microdialysis probe placed into AcbC (Panel C). Abbreviations: AcbC, nucleus accumbens,
core; CPU, caudate putamen; DRN, dorsal raphe nucleus, dorsal part; PLH, peduncular part of lateral hypothalamus.
doi:10.1371/journal.pone.0020766.g001
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of OEA or PEA into DRN (10, 20, or 30 mg/1 mL; each
compound) enhanced W (p,0.01) and diminished SWS (p,0.01)
as well as REMS (p,0.01; Figure 3B and Figure 3C, respectively).
We also found that URB597 and PEA induced a dose-dependent
effect in W and SWS.
Figure 2. Effects on total time (3 h of sleep recordings) of
wakefulness (W), slow wave sleep (SWS) and rapid eye
movement sleep (REMS) after administrations into the lateral
hypothalamus of either URB597 (Panel A), OEA (Panel B) or
PEA (Panel C). Pharmacological treatments (10, 20, 30 mg/1 mL; each
compound) increased W and diminished SWS as well as REMS (Mean 6
SEM of total time of recording [%]; * vs. Sham/Vehicle, p,0.05; # vs.
respective compound at 10 or 20 mg/1 mL, p,0.05).
doi:10.1371/journal.pone.0020766.g002
Figure 3. Effects on total time (3 h of sleep recordings) of W,
SWS and REMS after administrations into the dorsal raphe
nuclei of either URB597 (Panel A), OEA (Panel B) or PEA (Panel
C). Pharmacological treatments (10, 20, 30 mg/1 mL; each compound)
increased W and diminished SWS as well as REMS (Mean 6 SEM of total
time of recording [%]; * vs. Sham/Vehicle, p,0.05; # vs. respective
compound at 10 or 20 mg/1 mL, p,0.05; & vs. respective compound at
10 or 20 mg/1 mL, p,0.05).
doi:10.1371/journal.pone.0020766.g003
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URB597, OEA or PEA into LH
Current evidence suggest that power spectra bands provide
information about quality rather than quantity of sleep [24], thus
we analyzed fast Fourier transformation for alpha (for W; a=8–
12 Hz), delta (for SWS; d=0.5–4.0 Hz) and theta (for REMS;
h=6.0–12.0 Hz) after the pharmacological challenges. Injections
into LH of the highest dose of the compounds (30 mg/1 mL; each
compound) increased alpha (Figure 4A; p,0.05) whereas dimin-
ished delta (Figure 4B; p,0.05) and theta power (Figure 4C;
p,0.05).
Effects on power spectra after the microinjection of
URB597, OEA or PEA into DRN
We next sought to determine whether the injection of the drugs
(30 mg/1 mL; each compound) into DRN would induce significant
changes in power spectra. It was found that pharmacological trials
enhanced alpha (Figure 5A; p,0.05) but diminished delta
(Figure 5B; p,0.05) and theta power (Figure 5C; p,0.05).
Effects on dopamine extracellular levels after the
microinjection of URB597, OEA or PEA into LH
Next, we asked whether microinjections of URB597, OEA or
PEA (10, 20, 30 mg/1 mL; each compound) into LH may promote
an increase in the DA levels collected from AcbC. Concretely,
URB597 enhanced the DA contents (Figure 6A; p,0.01) whereas
OEA (Figure 6B; p,0.05) or PEA (Figure 6C; p,0.05) mimicked
these effects. Noteworthy, URB597 induced a dose-dependent
effect.
Effects on dopamine extracellular levels after the
microinjection of URB597, OEA or PEA into DRN
Finally, we tested whether injection of drugs (10, 20, 30 mg/
1 mL; each compound) into DRN could induce a significant
increase in the extracellular levels of DA collected from AcbC. As
predicted, URB597 enhanced the DA contents (Figure 7A;
p,0.001) and this effect was mimicked by OEA (Figure 7B,
p,0.001) or PEA (Figure 7C; p,0.001). We also found that OEA
induced a dose-dependent effect.
Discussion
The family of N-acylethanolamines includes the anoretic
mediator OEA, the anti-inflammatory component PEA, and the
first endocannabinoid to be described ANA. These compounds are
inactivated by the enzymatic hydrolysis, a process that is catalyzed
by the FAAH [1–3,9–15]. In recent years, different FAAH
inhibitors have been developed, such as URB597 [4–8].
The current study describes that microinjections of URB597,
OEA or PEA into wake-promoting brain areas, such as LH or
DRN, promote alertness and enhance DA levels. A lingering
question is whether the effects observed in the current report
would be mediated by ANA since the inactivation of FAAH by
URB597 increases the levels of this endocannabinoid. The wake-
promoting effects caused by URB597 might not likely caused by
elevated ANA levels since the endocannabinoid system has been
linked with sleep promotion. It is worth noting that the activation
of the CB1 cannabinoid receptor by the antagonist, SR141716A,
decreases sleep [25], systemic or central injections of ANA
promote sleep [26–28], higher levels of ANA have been described
in sleep-related brain regions [29], and the ANA membrane
transporter blocker, VDM-11, administered in rats promotes sleep
[30].
If URB597 increases levels of OEA, PEA and ANA, and this
last compound enhances sleep, how we can explain that injection
of the FAAH inhibitor induced waking? This discrepancy could be
attributed to the following possibility: Indeed, administrations of
URB597 enhance endogenous levels of ANA but with higher rates
for OEA and PEA [6]. It is therefore possible to conjecture that
ANA and URB597 could be promoting opposite effects in sleep by
Figure 4. EEG alpha (for W; a=8–12 Hz. Panel A), delta (for
SWS; d=0.5–4.0 Hz. Panel B) and theta (for REMS; h=6.0–
12.0 Hz. Panel C) power spectra (units, mV
2) in rats after the
following treatments into lateral hypothalamus: Sham, vehicle,
URB597, OEA or PEA (30 mg/1 mL; each compound). Data were
calculated over 3 consecutive hours at every time point (Mean 6 SEM;
* vs. Sham/Vehicle, p,0.05).
doi:10.1371/journal.pone.0020766.g004
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injections of the two ANA congeners, OEA or PEA, promote
waking [16]. Furthermore, endogenous levels of OEA and PEA
have been described higher in wake-related brain nuclei such as
pons and hypothalamus during the active period of the rat [29].
Aforementioned contributions to the role of OEA or PEA on
sleep-wake cycle seem to be favorable in terms of wake-modulating
properties.
An important question that remains to be addressed pertains to
the diffusion of URB597, OEA or PEA after injection. Solely
based on the obtained data and representing as a limitation of the
study, we are not able to exclude that the compounds are not
diffusing to other brain regions. Because our results indicate that
URB597, OEA or PEA enhanced alertness as well as DA levels, it
Figure 5. EEG alpha (for W; a=8–12 Hz. Panel A), delta (for
SWS; d=0.5–4.0 Hz. Panel B) and theta (for REMS; h=6.0–
12.0 Hz. Panel C) power spectra (units, mV
2) in rats after the
following treatments into dorsal raphe nuclei: Sham, vehicle,
URB597, OEA or PEA (30 mg/1 mL; each compound). Data were
calculated over 3 consecutive hours at every time point (Mean 6 SEM;
* vs. Sham/Vehicle, p,0.05).
doi:10.1371/journal.pone.0020766.g005
Figure 6. Extracellular levels of DA measured from AcbC
during 3 h after the administration into lateral hypothalamus
of URB597, OEA or PEA (10, 20, 30 mg/1 mL; each compound).
Each point represents Mean 6 SEM of pM (* vs. Sham/Vehicle, p,0.05;
# vs. respective compound at 10/20 mg/1 mL, p,0.05; & vs. respective
compound at 10 or 20 mg/1 mL, p,0.05).
doi:10.1371/journal.pone.0020766.g006
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other brain areas, it may be either LH or DRN vicinity. However,
it is tempting to hypothesize that the effects observed in this study
could be mediated by the activity of neurons placed in LH or
DRN. In this regard, it is known that both brain areas are key
elements in the modulation of waking [17–23,31].
The effects of the trials on alpha, delta and theta power spectra
are also significant. Since the EEG power gauges the potency of
multiple cortical-subcortical neuronal networks along different
firing frequencies [24], it is possible that the increase in the EEG
alpha power may reflect higher neuronal synchrony activated by
URB597, OEA or PEA. Nevertheless, the decrease in delta and
theta power in SWS and REM sleep, respectively, would suggest a
deficiency in sleep consolidation. Further experiments are needed
to determine whether effects in EEG power spectra can be related
with changes in activity of neurons related with generation of
power spectra.
The current study demonstrates that injection of URB597,
OEA or PEA either into LH or DRN increases DA levels collected
from AcbC. It is conceivable that these compounds could be
increasing alertness by enhancing DA levels. Several studies have
come to the conclusions that the axis accumbens-hypothalamus-
DRN plays a role in sleep modulation. For example, previous
studies have shown neuroanatomical projections from LH and
DRN to AcbC [32–34], the role of these brain nuclei on sleep
modulation [17–19,22,31] and yet the importance of DA in
waking has long been recognized [35].
In summary, injection of the FAAH inhibitor, URB597, as well
as the endogenous lipids, OEA and PEA promotes waking if
injected into wake-promoting brain area such as LH or DRN.
Furthermore, these compounds enhance the extracellular levels of
DA collected from AcbC. Despite that the current study has
several limitations and needs confirmation by performing larger
studies; it provides a framework for understanding the neurobi-
ological functions of FAAH as well as endogenous lipids such as
OEA and PEA on sleep modulation.
Materials and Methods
Male Wistar rats (250–300 g) were housed at constant
temperature (2161uC) and under a controlled light-dark cycle
(lights on: 07:00–19:00 h). All procedures were conducted in
accordance with the Mexican Institutes of Health Research (DOF.
NOM-062-Z00-1999) as well as the National Institutes of Health
Guide for the Care and Use of Laboratory Animals (NIH
publication No. 80-23, revised 1996) and the experimental
protocol was approved by the Committee on the Ethics of Animal
Experiments of our Institutions. All efforts were made to minimize
animal suffering, and to reduce the number of rats used.
Compounds were kindly provided by Professor Daniele Piomelli
(University of California, Irvine. USA) and were dissolved in
vehicle (VEH; composed of polyethylglycol/saline; 5:95 v/v).
Animals (n=8) were implanted for sleep studies with electrodes
to record the electroencephalogram (EEG) and electromyogram
(EMG) as well as a cannulae (23gauge) aimed either into LH
(A=23.3; L=61.6; H=28.2 mm [23]) or into DRN, dorsal
part (A=27.8; L=+0.2; H=27.1 [23]). The EEG/EMG data
was scored in 12 s epochs to determine W, SWS and REMS with
the aid of a sleep-scoring program (ICELUS). Power spectra bands
underly neurophysiological mechanisms of the sleep-wake cycle
and provide information about quality rather than quantity of
sleep, therefore, fast Fourier transformation analysis was collected
for alpha (for W; a=8–12 Hz), delta (for SWS; d=0.5–4.0 Hz)
and theta (for REMS; h=6.0–12.0 Hz). The sleep and power
spectra data were obtained during that period of time and were
analyzed as previously reported [30,36].
For the microdialysis experiment, a different group of rats
(n=8) was implanted with a guide-cannula (IC guide. BioAnalyt-
ical Systems, West Lafayette, IN, USA) into AcbC (target
coordinates: A=+1.2; L=2.0; H=27.0 [23]) as well as a
Figure 7. Extracellular levels of DA measured from AcbC
during 3 h period after the administration into dorsal raphe
nuclei of URB597, OEA or PEA (10, 20, 30 mg/1 mL; each
compound). Each point represents Mean 6 SEM of pM (* vs. Sham/
Vehicle, p,0.05; # vs. respective compound at 10/20 mg/1 mL, p,0.05;
& vs. respective compound at 10 or 20 mg/1 mL, p,0.05).
doi:10.1371/journal.pone.0020766.g007
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(coordinates described above). The microdialysis collection sample
procedure and neurochemical analysis for DA was developed as
previously reported [16]. Due that we have reported that
URB597, OEA and PEA modify sleep within a time frame of
3 h [16], sleep data and microdialysis samples were collected
exclusively during the same period of time.
At the beginning of the lights-on period (07:00 h), pharmaco-
logical trials were administered randomly as follows: VEH (n=8),
URB597 (n=8), OEA (n=8) or PEA (n=8). Different doses of
each compound were used (10, 20, 30 mg/1 mL) and to determine
whether the injection of VEH could modify the sleep-wake cycle
or the DA contents, an additional group (sham; n=8) was
included. In the whole study, injections were carried out slowly
over 1 mL/min.
Results are expressed as mean 6 SEM and the significance of
differences between groups was evaluated by one-way analysis of
variance (ANOVA) followed by the Scheffe ´’s post-hoc test (STAT-
VIEW). Differences were considered significant if p,0.05.
Author Contributions
Conceived and designed the experiments: EM-R. Performed the
experiments: EM-R MP-R DM-A. Analyzed the data: EM-R. Contributed
reagents/materials/analysis tools: RD-C. Wrote the paper: EM-R.
Analyzed the statistics: EM-R OA-C.
References
1. Schmid HH, Schmid PC, Natarajan V (1996) The N-acylation-phosphodies-
terase pathway and cell signalling. Chem Phys Lipids 80: 133–142.
2. Hansen HS (2010) Palmitoylethanolamide and other anandamide congeners.
Proposed role in the diseased brain. Exp Neurol 1: 48–55.
3. Ahn K, McKinney MK, Cravatt BF (2008) Enzymatic pathways that regulate
endocannabinoid signaling in the nervous system. Chem Rev 108: 1687–1707.
4. Kathuria S, Gaetani S, Fegley D, Valin ˜o F, Duranti A, et al. (2003) Modulation
of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76–81.
5. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, et al. (2003)
Cyclohexylcarbamic acid 39-o r4 9-substituted biphenyl-3-yl esters as fatty acid
amide hydrolase inhibitors: synthesis, quantitative structure-activity relation-
ships, and molecular modeling studies. J Med Chem 47: 4998–5008.
6. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, et al. (2005)
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic
acid 39-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and
oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352–358.
7. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, et al. (2006)
Pharmacological profile of the selective FAAH inhibitor KDS-4103
(URB597). CNS Drug Rev 12: 21–38.
8. Tarzia G, Duranti A, Tontin A, Piersanti G, Mor M, et al. (2003) Design,
synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a
new class of fatty acid amide hydrolase inhibitors. J Med Chem 46: 2352–2360.
9. Rodrı ´guez de Fonseca F, Navarro M, Go ´mez R, Escuredo L, Nava F, et al.
(2001) An anorexic lipid mediator regulated by feeding. Nature 414: 209–212.
10. Gaetani S, Oveisi F, Piomelli D (2003) Modulation of meal pattern in the rat by
the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacol 28:
1311–1316.
11. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, et al. (2003)
Oleylethanolamide regulates feeding and body weight through activation of
the nuclear receptor PPAR-alpha. Nature 425: 90–93.
12. Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, et al. (2008) The lipid messenger
OEA links dietary fat intake to satiety. Cell Metab 8: 281–288.
13. Calignano G, La Rana G, Piomelli D (2001) Antinociceptive activity of the
endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419:
191–198.
14. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, et al. (2001) Inhibitory effect
of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol
134: 945–950.
15. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, et al. (2005) The nuclear
receptor peroxisome proliferator-activated receptor-alpha mediates the anti-
inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15–19.
16. Murillo-Rodrı ´guez E, Va ´zquez E, Milla ´n-Aldaco D, Palomero-Rivero M,
Drucker-Colı ´n D (2007) Effects of the fatty acid amide hydrolase inhibitor
URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the
rat. Eur J Pharmacol 562: 82–91.
17. Jones BE (2005) From waking to sleeping: neuronal and chemical substrates.
Trends Pharmacol Sci 11: 578–586.
18. Llina ´s RR, Steriade M (2006) Bursting of thalamic neurons and states of
vigilance. J Neurophysiol 95: 3297–308.
19. Steriade M (2006) Grouping of brain rhythms in corticothalamic systems.
Neurosci 137: 1087–106.
20. Dzirasa K, Ribeiro S, Costa R, Santos LM, Lin SC, et al. (2006) Dopaminergic
control of sleep-wake states. J Neurosci 26: 10577–10589.
21. Monti JM, Monti D (2007) The involvement of dopamine in the modulation of
sleep and waking. Sleep Med Rev 11: 113–133.
22. Jones BE (2005) From waking to sleeping: neuronal and chemical substrates.
Trends Pharmacol Sci 26: 578–586.
23. Paxinos G, Watson C (2005) The Rat Brain in Stereotaxic Coordinates. New
York: Academic Press.
24. Corsi-Cabrera M, Pe ´rez-Garci E, Del Rio-Portilla Y, Ugalde E, Guevara MA
(2001) EEG bands during wakefulness, slow-wave, and paradoxical sleep as a
result of principal component analysis in the rat. Sleep 24: 374–380.
25. Santucci V, Storme JJ, Soubrie ´ P, Le Fur G (1996) Arousal-enhancing properties
of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by
electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 58:
PL103–10.
26. Murillo-Rodrı ´guez E, Sa ´nchez-Alavez M, Navarro L, Martı ´nez-Gonza ´lez D,
Drucker-Colı ´n R, et al. (1998) Anandamide modulates sleep and memory in rats.
Brain Res 812: 270–274.
27. Murillo-Rodrı ´guez E, Cabeza R, Me ´ndez-Dı ´az M, Navarro L, Prospe ´ro-
Garcı ´a O (2001) Anandamide-induced sleep is blocked by SR141716A, a CB1
receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport
12: 2131–2136.
28. Murillo-Rodrı ´guez E, Blanco-Centurio ´n C, Sa ´nchez C, Piomelli D,
Shiromani PJ (2003) Anandamide enhances extracellular levels of adenosine
and induces sleep: an in vivo microdialysis study. Sleep 26: 943–947.
29. Murillo-Rodrı ´guez E, De ´sarnaud F, Prospe ´ro-Garcı ´a O (2006) Diurnal variation
of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide
in the brain of the rat. Life Sci 1: 30–37.
30. Murillo-Rodrı ´guez E, Milla ´n-Aldaco D, Di Marzo V, Drucker-Colı ´n R (2008)
The anandamide membrane transporter inhibitor, VDM-11, modulates sleep
and c-Fos expression in the rat brain. Neurosci 11: 1–11.
31. Murillo-Rodrı ´guez E, Arias-Carrio ´n O, Sanguino-Rodrı ´guez K, Gonza ´lez-
Arias M, Haro R (2009) Mechanisms of sleep-wake cycle modulation. CNS
Neurol Disord Drug Targets 8: 245–253.
32. Haber SN, Groenewegen HJ, Grove EA, Nauta WJ (1985) Efferent connections
of the ventral pallidum: evidence of a dual striato pallidofugal pathway. J Comp
Neurol 235: 322–335.
33. Stratford TR, Wirtshafter D (1990) Ascending dopaminergic projections from
the dorsal raphe nucleus in the rat. Brain Res 511: 173–176.
34. Zahm DS, Heimer L (1993) Specificity in the efferent projections of the nucleus
accumbens in the rat: comparison of the rostral pole projection patterns with
those of the core and shell. J Comp Neurol 327: 220–232.
35. Monti JM, Jantos H (2008) The roles of dopamine and serotonin, and of their
receptors, in regulating sleep and waking. Prog Brain Res 172: 625–646.
36. Murillo-Rodrı ´guez E, Milla ´n-Aldaco D, Palomero-Rivero D, Mechoulam R,
Drucker-Colı ´n D (2008) The non-psychoactive cannabis constituent cannabidiol
is a wake-inducing agent. Behav. Neurosci 122: 1378–1382.
URB597 Promotes Wakefulness in Rats
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e20766